<DOC>
	<DOC>NCT00944645</DOC>
	<brief_summary>This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.</brief_summary>
	<brief_title>MK0524A Bioequivalence Study (0524A-059)</brief_title>
	<detailed_description />
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Subject is in good health Subject is willing to follow all study guidelines Subject has or has a history of any disease or condition that might confound the results of the study or make participation unsafe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>